Guest Editors
Dr. Magdalena Mizerska-Kowalska
Email: magdalena.mizerska-kowalska@mail.umcs.pl
Affiliation: Department of Virology and Immunology, Institute of Biological Sciences, Faculty of Biology and Biotechnology, Maria Curie-Sklodowska University, Lublin, Poland
Homepage:
Research Interests: osteosarcoma, immunomodulation, tumor‑bone microenvironment
Dr. Aurélie Dutour
Email: aurelie.dutour@lyon.unicancer.fr
Affiliation: Team Cell Death and Pediatric Cancer, Cancer Initiation and Tumour Cell Identity Department, Cancer Research Center of Lyon, Lyon, France
Homepage:
Research Interests: osteosarcoma, tumor microenvironment, tumor–immune interactions, immunomodulatory therapeutic, translational oncology
Prof. Roman Paduch
Email: roman.paduch@mail.umcs.pl
Affiliation: Department of Virology and Immunology, Institute of Biological Sciences, Faculty of Biology and Biotechnology, Maria Curie-Sklodowska University, Lublin, Poland
Homepage:
Research Interests: tumor microenvironment, tumor-normal cell interactions, immunology of tumor metastasis, laryngeal cell carcinomas, colorectal cancer cells
Summary
The osteosarcoma (OS) is the most common type of primary bone malignancy, with an incidence rate of 2–4/million/year worldwide. It predominantly affects children and adolescents, as well as people over approximately 60 years of age. However, current statistics of prognosis for diagnosed and treated patients are promising, but the survival rate, 20%–30%, is still dismal in patients with metastasis, primarily to the lungs. The current regimes for treatment are chemotherapy and surgery with pre- and post-operative adjuvant chemotherapy, sometimes supported with radiotherapy, and have remained unchanged since the 1980s. Unfortunately, the chemotherapy, together with radiotherapy, is characterized by toxicity and low selectivity. They result in tumor recurrence, metastasis, and the development of chemotherapy resistance. Hence, there is still demand for searching for new strategies of osteosarcoma treatment, e.g., directed to other molecular targets in comparison with currently used drugs which main mechanism of activity is interference with DNA synthesis, replication, and transcription. Taking into account the above issues, this Special Issue is open to submissions of recent studies or literature reviews on newly discovered targets and anticancer agents regarding the development of new therapeutic methods to be used in osteosarcoma.
Keywords
osteosarcoma, osteosarcoma biomarkers, cellular and molecular mechanisms in osteosarcoma, implication of bone microenvironment in osteosarcoma, novel therapeutic targets, immunotherapies
Login
Register
Submit a Paper
Propose a Special lssue